## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.5% in lower entry zone (4.0-10.0%), top quartile (89th pct) cross-sectional ranking. Caution: MRS_5 (-0.4%) diverging from MRS_20, watch for reversal. Outperforming sector by 4.7%. Caution: declining volume (48% of avg), momentum weakening (-3.1% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($76.06)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025**
- Source: Markets Financial Content | 20251130T150000 | Bullish | Relevance: 99%
- GE HealthCare (Nasdaq: GEHC) is set to showcase over 40 transformative innovations at RSNA 2025, building on its century-long legacy in medical imaging. The company has invested over $3 billion in R&D since 2022, focusing on AI-enabled and cloud-based solutions to address healthcare challenges like staff shortages and demand for imaging services. Key innovations include advanced CT and MRI systems, a 3D mammography reconstruction technology, and new cardiovascular ultrasound platforms, alongside a robust portfolio of FDA-authorized AI solutions.

**2. GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025**
- Source: Business Wire | 20251130T150611 | Bullish | Relevance: 99%
- GE HealthCare is showcasing transformative innovations at RSNA 2025, building on over a century of medical technology advancements. The company has invested more than $3 billion in R&D since 2022 to develop AI-enabled and cloud-based solutions, including new CT, MRI, mammography, and ultrasound technologies, alongside advanced radiopharmaceuticals, aiming to address critical challenges in radiology departments. These innovations aim to improve diagnostic precision, enhance operational efficiency, and advance personalized patient care.

**3. Latest SIGNA MRI Technology from GE Healthcare Helps Boost Efficiency, Enhance Patient Experience and Advance Sustainability**
- Source: Imaging Technology News | 20251201T205554 | Bullish | Relevance: 99%
- GE HealthCare has announced 510(k) submissions to the FDA for its next-generation SIGNA MRI technology, including the SIGNA Bolt 3T MRI scanner and SIGNA Sprint with Freelium 1.5T system. These innovations are designed to boost efficiency, enhance the patient experience, and advance sustainability in MRI by incorporating AI-powered workflows, advanced applications, and reduced helium usage. The new systems aim to address challenges like long wait times and clinician burnout while expanding access to advanced MR capabilities.

**4. GE HealthCare to showcase innovations at RSNA 2025 meeting**
- Source: TipRanks | 20251130T183622 | Bullish | Relevance: 99%
- GE HealthCare (GEHC) announced its plans to showcase significant innovations at the Radiological Society of North Americaâ€™s (RSNA) 2025 Annual Meeting. The featured innovations will include Photonova Spectra, next-gen SIGNA MRI technology, Pristina Recon DL, Vivid Pioneer, Flyrcado injection, and Definium Pace Select, highlighting the company's commitment to advancing precision care.

**5. GE HealthCare Technologies prices $1.25 billion in new notes offering**
- Source: Investing.com | 20251202T170500 | Somewhat-Bullish | Relevance: 99%
- GE HealthCare Technologies announced the pricing of a $1.25 billion underwritten public offering of senior notes, consisting of $600 million at 4.150% due December 15, 2028, and $650 million at 4.950% due December 15, 2035. Despite the new debt, the company maintains a reasonable debt-to-equity ratio of 1.08 and an Altman Z-Score of 2.66, indicating moderate financial stability. This comes alongside other recent news, including a quarterly cash dividend and regulatory applications for new imaging technologies.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.6B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 16.3 |
| Current P/E | 17.6 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 7.6% to 4.5% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 (-0.4%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.3% shows strong absolute momentum above own 20MA. Outperforming sector by 4.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.75), confirming momentum. Volume at 48% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.47% (CS: 89) | Strong |
| RSI_14 | 63.6 | Neutral |
| MACD Histogram | 0.75 | Bullish |
| vs SMA20 | 1.063x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $80.22
- **Stop Loss:** $76.06 (5.2% risk)
- **Target:** $86.46 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 240
- **Position Value:** $19,252.80
- **Portfolio %:** 19.25%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*